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Antiretroviral Treatment for Pregnant Women Living with 
HIV: A Summary of Issues, Interventions, and Evidence 
 
Antiretroviral treatment (ART) for women living with HIV is vital to ensuring safe 
motherhood and reducing vertical transmission. Each year, as many as 42,000 women 
living with HIV die of HIV and pregnancy-related complications (Glass and Birx, 2016). 
While significant progress has been made with 93% of pregnant women in 22 priority 
countries who have accessed combination ART (or cART, formerly called HAART), not 
all pregnant women can access treatment. In low- and middle-income countries in 
particular, treatment access for pregnant women living with HIV has been hampered by 
availability of medications and standardized treatment eligibility criteria that traditionally 
prioritized prevention of HIV transmission to the infant over treatment for the health of 
the woman. 
 
Treatment Guidance Has Changed Dramatically  
WHO’s September 2015 guidance states that 
“ART should be initiated in all pregnant and 
breastfeeding women living with HIV at any 
CD4 cell count and continued lifelong,” 
(WHO, 2015f: 13), a treatment regimen also 
known as Option B+.  Global inequality may 
be reduced now that there is global agreement 
on when to start treatment. However, not all 
women will benefit immediately. The reality is 
that, in 2015, fewer than one out of 10 people 
living with HIV live in a country where ART upon HIV diagnosis is current policy or 
practice (Health Gap, 2015). 
 
Antiretroviral Medications are Beneficial, But Drug Resistance Remains a Concern for 
Women Living with HIV 
Concerns about taking cART during pregnancy are outweighed by the benefits.  Studies 
show that women living with HIV who access ART prior to pregnancy or very early in 
pregnancy have no differences in rates of birth defects in fetuses/infants with first 
trimester use of ART compared with ART initiation later in pregnancy (USHHS, 2015: c-
 
This section does not provide medical 
or clinical guidance, which is 
available from WHO, but rather a 
public health perspective on what 
works for women in access and 
adherence to ART in the context of 
antenatal care.  
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6). Since Option B+ calls for lifelong treatment, women living with HIV are at lesser risk 
of developing drug resistance, unless they stop and start the recommended treatment, are 
non-adherent, face drug stockouts, receive inappropriate regimens, etc.. Some women 
may face worse outcomes on cART due to earlier WHO-recommended regimens during 
previous pregnancies.  
 
All Women Living with HIV Need Timely Access to ART, Ideally Prior to Pregnancy 
Adolescent girls are especially important in antenatal care treatment programming 
because of their increased vulnerability. Women who are part of key populations, such as 
women who use drugs and women who are sex workers, also need intensified 
programming to ensure ART access. “Motherhood is common among female sex 
workers,” yet sex workers fear health services or avoid services, due to stigma and 
discrimination (Papworth et al, 2015; S154).   
 
Women’s Lives Are as Important as Their Children’s 
Maternal HIV status and health is key to survival for infants and children in the post-
neonatal period.  A recent study in Malawi found that the mother’s HIV-positive status 
correlated with more than one-third of deaths of children up to age four. Children whose 
mothers died were at greater risk of dying than those whose mothers were alive (Chihana 
et al., 2015). Focus group discussions among women living with HIV in Malawi found 
that Option B+ is presented to women as a program primarily to protect the baby, with 
their health unimportant (Hsieh, 2013). 
	
Few countries have comprehensive registers that follow the mother-infant pair after 
delivery to measure longer-term cART adherence (UNAIDS, 2015). In order to 
adequately assess if mothers are adhering well and are being kept alive, national 
governments should continue to track: 
• What % of pregnant women living with HIV access ANC and cART (Dourado et 
al., 2014; Hlarlaithe et al., 2014); 
• What % of pregnant women living with HIV are virally suppressed with cART; 
• What % of women living with HIV who remain virally suppressed with cART by 
number of years postpartum. 
	
Women Need Information, Support and Respect in Decision-Making About 
Antiretroviral Therapy 
While WHO does not specify how quickly a 
pregnant woman should initiate cART upon 
an HIV-positive diagnosis, countries that are 
implementing Option B+ are interpreting the 
guidance to mean immediately. Yet initiating 
treatment upon diagnosis may be too 
challenging for some pregnant women. 
Women in South Africa noted that they faced 
a triple burden of transitioning into 
pregnancy, accepting a new HIV-positive serostatus and recognizing the need to start 
lifelong ART as soon as possible (Stinson and Myer, 2012). Insufficient counseling or 
 
“I was really in favour of early 
treatment and to have this Option 
B+. But now my worry is: are we 
being given this as an option or is 
this being pushed on us with no 
option?” -Woman living with HIV in 
Zimbabwe (ATHENA et al., 2015: 3).  
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respect for women’s decision-making time can drive women away from accessing 
treatment. 
 
Fear of Disclosure, Violence Can Influence Treatment Initiation and Adherence 
Pregnant women living with HIV still remain highly stigmatized in many countries. 
While “disclosure of one’s HIV status can help to improve uptake and retention in 
prevention of mother-to-child transmission of HIV services…” (Tam et al., 2015: 436), 
some women are reluctant to disclose, particularly to their sexual partners (Croce-Galis et 
al., 2015). As one woman living with HIV, diagnosed during pregnancy, put it: “…I 
won’t tell him, because I need him, because he helps me with money. I can’t lose him 
now because I can’t manage to have this baby if he doesn’t support me” (Sewnunam and 
Modiba, 2015: 63). In some cases, disclosure may place a pregnant woman at risk. For 
example, pregnant women in Zimbabwe have faced violence for testing without their 
partner’s consent (Shamu et al., 2014). 
	
Addressing Gender Norms and Supporting Women May be Key to Eliminating Vertical 
Transmission 
Women may face other gender related barriers to accessing health services (Croce-Galis 
et al., 2015), as one woman noted in Cote d’Ivoire, who said that her husband would not 
give her the funds to get transport to services (Schechter et al., 2014). A barrier to 
initiation, adherence and retention on ART for pregnant women living with HIV is that 
she may be required to ask permission to access services (Hodgson et al., 2014; 
Hlarlaithe et al., 2014). Key to gender transformative programming in Safe Motherhood 
and Prevention of Vertical Transmission is for women’s lives to be valued – not just to 
keep babies healthy. Community-based support programs for pregnant women living 
with HIV can be helpful. A recent study of implementation of community-based 
adherence clubs for stable ART patients, which provided ART to 2,133 patients, 71% 
female, with a strong emphasis on peer-based support and patient self management, 
found that one year later, only 6% of patients were lost to follow up and fewer than 2% of 
patients experienced viral load rebound (Grimsrud et al., 2015). 
 
Additional Efforts are Needed to Better Engage Men in Supporting Safe Motherhood 
and Prevention of Vertical Transmission  
Little work has been done to explain vertical transmission to male partners and how men 
can support pregnant partners living with HIV (Auvinen et al., 2014b). Interviews with 
male partners of pregnant women living with HIV in South Africa found that men felt 
responsible for their children, but that long clinic lines and the view that clinics for 
maternal health care are women-only spaces reduced the likelihood that men will access 
services through antenatal care (Koo et al., 2013a). Remarkably little is known about 
couples and their relationships in the context of HIV and how to improve couple 
communication around sensitive topics around risk, sex and transmission (Ramirez-
Ferrero and Lusti-Narasimhan, 2012). More nuanced efforts are needed to engage men in 
prevention of vertical transmission.   
 
It IS Possible to Eliminate Vertical Transmission 
Between 2009 and 2015, there has been a 46% decline in the number of AIDS-related 
deaths among women of reproductive age in the 21 priority countries (UNAIDS, 2016), a 
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remarkable achievement. In June 2015, Cuba became the first country to be validated as 
having met the global criteria for eliminating vertical transmission as a public health 
problem, that is, in 2014, fewer than 50 new infections in 100,000 live births; a rate of  
under 5% in breastfeeding women and less than 2% among women who do not breastfeed 




The following interventions have been successful in improving treatment for pregnant 
women living with HIV.  See www.whatworksforwomen.org for more details, including 
full citations, detailed methodology, and critical gaps in the literature. 
	
What Works—Safe Motherhood and Prevention of Vertical Transmission: Antenatal 
Care – Treatment  
 
1. Initiating cART as early as possible to achieve low viral load is optimal, improves 
maternal health, and reduces risk of vertical transmission. Supported by 19 studies in 30 
countries	
2. Peer counseling by mother mentors may improve treatment adherence among pregnant 
women living with HIV. Supported by 6 studies in 8 countries 
3. Community health workers and community-based support can increase uptake of safe 
motherhood interventions for women living with HIV and reduce vertical transmission. 
Supported by 9 studies in 7 countries 
4. PMTCT-Plus (family-focused) HIV care can increase the numbers of women and their 
partners who access treatment and remain adherent. Supported by 4 studies in 9 countries 
5. Integrating ARV therapy into antenatal care, rather than referring women separately for 
HIV treatment, can reduce time to treatment and increase adherence for pregnant women 
living with HIV. Supported by 10 studies in 5 countries 
6. National scale-up of cART in pregnancy improves maternal and infant outcomes. 




What Works for Women and Girls is supported by the U.S. President’s Emergency Plan 
for AIDS Relief (PEPFAR) and is carried out under the auspices of USAID’s Evidence 
Project and What Works Association. 
 
For more information please visit www.whatworksforwomen.org 
 
 
Suggested Citation: Gay, Jill, Melanie Croce-Galis, Karen Hardee, and Mackenzie Kacmarcik. 
2016. “Antiretroviral Treatment for Pregnant Women Living with HIV: A Summary of Issues, 
Interventions, and Evidence,” Washington, DC: Population Council, The Evidence Project and 
What Works Association.  
 
